Hujanen E S, Väisänen A, Zheng A, Tryggvason K, Turpeenniemi-Hujanen T
Institute of Dentistry, University of Oulu, Finland.
Int J Cancer. 1994 Aug 15;58(4):582-6. doi: 10.1002/ijc.2910580422.
The purpose of this study was to determine how interferons alpha and gamma influence the expression of M(r) 72,000 type-IV collagenase (gelatinase A) and M(r) 92,000 type-VI collagenase (gelatinase B) genes and whether there are differences in their gene expression. Special emphasis was focused on the treatment time. Total cellular RNA from A2058 human melanoma cells treated for various time periods with IFN-alpha or gamma was analyzed by Northern- and slot-blot hybridization. Both M(r) 72,000 and M(r) 92,000 type-IV collagenase mRNAs were detectable in A2058 cells and mRNA levels for both gelatinases were significantly up-regulated in the cells treated for a short time period with either IFN-alpha or gamma. In contrast, a long-term treatment (7 days) with these drugs markedly down-regulated the genes for both gelatinase A and B. Zymographic analysis showed that human melanoma primarily secretes the gelatinase-A activity, which showed changes similar to those seen in the corresponding mRNA after the treatments with interferons. The expression of gelatinase-B activity was, however, detectable only transiently during the stimulating phase with IFN-alpha. Western immunoblot analysis showed that alterations in the levels of immunoreactive protein of gelatinase A in the cells correlated with the mRNA levels after the treatments. These findings suggest that IFN-alpha and IFN-gamma are potent regulators of both M(r) 72,000 and M(r) 92,000 type-IV collagenase/gelatinase A and B genes in human melanoma showing biphasic and parallel effects on mRNA levels of both enzymes, depending on the treatment time, and that the M(r) 72,000 metalloproteinase/gelatinase A is the predominant basement-membrane-degrading type-IV collagenase in human melanoma.
本研究的目的是确定α干扰素和γ干扰素如何影响72000分子量的IV型胶原酶(明胶酶A)和92000分子量的VI型胶原酶(明胶酶B)基因的表达,以及它们的基因表达是否存在差异。特别强调了治疗时间。通过Northern印迹和狭缝印迹杂交分析了用α干扰素或γ干扰素处理不同时间段的A2058人黑色素瘤细胞的总细胞RNA。在A2058细胞中可检测到72000分子量和92000分子量的IV型胶原酶mRNA,用α干扰素或γ干扰素短时间处理的细胞中两种明胶酶的mRNA水平均显著上调。相反,用这些药物长期处理(7天)可显著下调明胶酶A和B的基因。酶谱分析表明,人黑色素瘤主要分泌明胶酶A活性,其变化与用干扰素处理后相应mRNA的变化相似。然而,明胶酶B活性仅在α干扰素刺激阶段短暂可检测到。Western免疫印迹分析表明,处理后细胞中明胶酶A免疫反应性蛋白水平的变化与mRNA水平相关。这些发现表明,α干扰素和γ干扰素是人类黑色素瘤中72000分子量和92000分子量的IV型胶原酶/明胶酶A和B基因的有效调节因子,根据治疗时间对两种酶的mRNA水平呈现双相且平行的影响,并且72000分子量的金属蛋白酶/明胶酶A是人类黑色素瘤中主要的降解基底膜的IV型胶原酶。